Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com -- DaVita Inc . (NYSE:DVA) reported first quarter 2025 financial results that modestly exceeded analyst expectations, with earnings and revenue coming in slightly above consensus estimates. The kidney care services provider’s stock was unchanged in after-hours trading following the release.
DaVita posted adjusted earnings per share of $2.00 for the quarter, beating the analyst estimate of $1.96. Revenue came in at $3.22 billion, just above the $3.2 billion consensus forecast. Compared to the same quarter last year, revenue increased 5.1% from $3.06 billion.
"Our strong first quarter performance demonstrates the stability and consistency of our operating model," said Javier Rodriguez, CEO of DaVita Inc.
The company reported operating income of $439 million for the quarter, representing an operating margin of 13.6%. Total (EPA:TTEF) U.S. dialysis treatments increased 0.01% compared to the previous quarter, averaging 91,793 treatments per day.
DaVita repurchased 3.7 million shares of its common stock during the quarter at an average price of $148.94 per share, totaling $550 million. The company continued share repurchases after the quarter end, buying back an additional 1.7 million shares for $259 million through May 12.
For the full year 2025, DaVita expects adjusted operating income between $2.01 billion and $2.16 billion and adjusted diluted earnings per share of $10.20 to $11.30.
The company’s outlook and results reflect its ongoing focus on operational efficiency and returning value to shareholders, as highlighted by its share repurchase activity and steady treatment volume growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.